Apart from restraining tumor growth via the cholesterol depletion-mediated pathway, more studies have shown that PCSK9 inhibition can also potentiate the effects of PD-1/PD-L1 blockades, which suggests a novel approach for tumor treatment (Table 2). Here, CD274 is linked to neoplasm.